Mallinckrodt Inc

Mallinckrodt — Merger or Acquisition (March 2025)

16 slides from Mallinckrodt's merger presentation, Mar 13, 2025

  1. Slide 1: Project Salvare Discussion Materials February 2025

    CONFIDENTIAL Project Salvare DISCUSSION MATERIALS FEBRUARY 2025

  2. Slide 2: Table of Contents

    CONFIDENTIAL Table of Contents PROJECT SALVARE Preliminary Value Creation Analysis of a Potential Transaction Overview of a Potential Generics Separation 4 Appendix Strategic Perspectives on a Potential Transaction 2 3 1

  3. Slide 3: Executive Summary

    Executive Summary PROJECT SALVARE 3 Preliminary and Illustrative • Given the clear alignment of the Macaw and Eagle businesses, a combination offers a unique opportunity to create two leading, scaled businesses in Specialty Brands and Generics • The transaction has a clear and powerful industrial ra

  4. Slide 4: Preliminary Deal Structure and Rationale

    Preliminary Deal Structure and Rationale PROJECT SALVARE Macaw Eagle Combined Company Specialty Generics Business Specialty Brands Business Step 1 Step 2 Combination of Macaw and Eagle Businesses I TRANSACTION OVERVIEW Observations • Merger and subsequent separation to create: i) a leading, scaled S

  5. Slide 5: Opportunity for Significant Value Creation by Creating Leading Specialty Pharma and Generics Companies

    Opportunity for Significant Value Creation by Creating Leading Specialty Pharma and Generics Companies PROJECT SALVARE I TRANSACTION OVERVIEW 5 Strategic Perspectives on a Potential Transaction 1 GenericsCo Presents Opportunity to Return Capital to Investors Leverage Capacity for Brands Business Tax

  6. Slide 6: Structural Considerations

    Structural Considerations PROJECT SALVARE 6 Strategic Perspectives on a Potential Transaction 1 Preliminary and Illustrative Small manufacturing designation under the IRA Irish tax domicile / structure Minimized change of control payments 1 2 3

  7. Slide 7: Significant Operating Synergies Available from Combination

    Significant Operating Synergies Available from Combination ($ in millions) PROJECT SALVARE I TRANSACTION OVERVIEW 7 Strategic Perspectives on a Potential Transaction 1 Note: Equity compensation is excluded from current figures. Excludes one-time impacts and separation dis-synergies. 1 $180mm of syne

  8. Slide 8: Potential Combination Creates Financial Flexibility for Pro Forma Business

    Potential Combination Creates Financial Flexibility for Pro Forma Business ($ in millions) PROJECT SALVARE GenericsCo Net Leverage 0.5x 1.0x 1.5x 2.0x 2.5x 3.0x 3.5x BrandsCo Net Leverage 3.2x 2.9x 2.5x 2.2x 1.9x 1.5x 1.2x Source: Eagle LRP, Macaw LRP, Company Filings. Note: Net debt based on estima

  9. Slide 9: Pro Forma Generics Business Focused Combined GenericsCo Creates Opportunity for Yield

    Pro Forma Generics Business Focused Combined GenericsCo Creates Opportunity for Yield PROJECT SALVARE 9 Preliminary and Illustrative PF Generics Business Profile Specialty Generics Equity Story Commentary $1.7bn 2025E Total Revenue ~$230mm Levered Free Cash Flow1 ~28% 2025E EBITDA Margin Eagle Steri

  10. Slide 10: CombinedCo Valuation – Sum-of-the-Parts

    6,855 Range of $6,314- $6,748mm depending on assumed multiple uplift (0.00x – 0.75x range) Eel Macaw Brands Eagle Brands Macaw Gx Eagle Gx Eagle SI Op. Synergies1 Tax Synergies1 Overhead EV Net Debt EqV Multiple Rerating2 EqV incl. Multiple Upside Est. ’25E EBITDA $244 $509 $310 $111 $113 $180 ($180

  11. Slide 11: BrandsCo SOTP Valuation

    PROJECT SALVARE Macaw Brands Eagle Brands Op. Synergies1 Tax Synergies1 Overhead EV Net Debt EqV Multiple Uplift2 EqV Est. ’25E EBITDA $244 $509 $180 ($122) $811 $7213 $721 Illustrative Blended Multiple 6.5x 7.0x 6.8x 6.8x 7.2x 1.9x 0.75x BrandsCo SOTP Valuation1 Source: Macaw LRP. Eagle LRP. Note:

  12. Slide 12: Implied Share Price from Levered FCF Yield

    $230mm PROJECT SALVARE • Estimated levered FCF based on Macaw and Eagle Generics and Eagle Sterile Injectables cash flows with overhead allocated by % sales contribution − Assuming $1,190mm net debt raised at the Generics NewCo level based on a net leverage ratio of 2.5x ’25E PF EBITDA (45% LTV base

  13. Slide 13: Illustrative Value Creation Analysis – Macaw Value Creation

    Illustrative Value Creation Analysis – Macaw Value Creation ($ in millions) PROJECT SALVARE Macaw Value Creation Macaw Current Market Value PF BrandsCo Pre Rerating PF GenericsCo (15% LFCF Yield)2 Multiple Uplift3 PF Value to Macaw S/H (post-multiple uplift) Total Equity Value 1,976 4,523 1,533 0 –

  14. Slide 14: Eagle Value Creation

    Eagle Value Creation Source: Macaw LRP. Eagle LRP. Note: Eagle LRP net sales forecast revised to reflect Macaw diligence. SOTP-implied equity value with overhead allocated by % sales contribution for Eagle and overhead fully allocated to Macaw’s Brands business and valued at SOTP-implied blended mul

  15. Slide 15: Value Creation Sensitivity – Macaw Shareholders

    Value Creation Sensitivity – Macaw Shareholders PROJECT SALVARE 15 Value Creation Based on Dividend to Eagle Shareholders at Ownership Split of 50.5% (Macaw) and 49.5% (Eagle) $ Dividend to Eagle Shareholders $120 $150 $180 $210 $240 Based on Current Market Value of $100 / share 0.00x (7.2x) 55% 54%

  16. Slide 16: Disclaimer

    CONFIDENTIAL Disclaimer PROJECT SALVARE The information herein has been prepared based in part upon information supplied by Endo International plc (“Eagle”) or publicly available information, and portions of the information herein may be based upon certain statements, estimates and forecasts with re

Mallinckrodt — Merger or Acquisition (March 2025) on 6ix